On November 5, EVEREST MED recorded an Intraday Rise of 5.67% in Regular Trading, with the stock trading at HK$28.08 and turnover of HK$34.35 million.
The move was accompanied by continued market attention on two recent developments: the company disclosed its October monthly share movement report, showing 172,150 new ordinary shares issued from post-IPO option exercises, while 8,427 options lapsed; separately, its latest mRNA R&D day highlighted progress in its in-house AI neoantigen prediction and mRNA/LNP platform.
Background disclosures indicate the mRNA platform now spans personalized neoantigen vaccines, off-the-shelf tumor vaccines, immune-modulatory vaccines and in vivo CAR-T, with EVM16 already generating initial human data and EVM14 advancing clinically. The share issuance was modest relative to total capital, but the combination of clinical-platform updates and ongoing equity incentive conversion appears to have kept investor focus on execution and pipeline validation.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments